Sleep-Wake Disorders

Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.

Carlos H. Schenck, MD, delivered the keynote address at SLEEP 2026 on REM sleep behavior disorder. Here's what psychiatrists and mental health clinicians need to know.

Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

Learn why insomnia and daytime sleepiness signal psychiatric risk, and how screening for apnea, delayed phase, and fatigue sharpens treatment.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

Sleep disorders commonly occur in young patients with ADHD. See how to monitor and treat these issues.

Stroke recovery lasts years; learn why fatigue, sleep, hormones and cognition demand ongoing rehab beyond 90 days—and how progress can continue.

Learn more about the effect of sleep on coaches and athletic teams.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Elite coaches often run on severe sleep loss, risking impaired decisions, emotion control, and leadership.

New Sleep in America poll reveals kids fall short on sleep, parents underestimate needs, and family wellbeing suffers.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

Sleep is vital for athlete patients, enhancing performance, mental health, and recovery. Discover effective strategies to optimize sleep for peak athletic success.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Explore the complexities of insomnia treatment, highlighting the limited role of melatonin and the effectiveness of cognitive behavioral therapy for better sleep.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Explore the complexities of insomnia in older adults, its impact on health, and effective management strategies for improved sleep quality.

Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Sleep disruption undermines team coordination in sports, revealing its critical role in collective performance and strategic success.